Company profile for Immatics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT...
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Paul-Ehrlich-Str. 15 72076 Tuebingen Germany
Telephone
Telephone
+49 (7071) 5397-0
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/05/3200531/0/en/Immatics-Announces-125-Million-Underwritten-Offering.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/11/17/3188995/0/en/Immatics-Announces-Third-Quarter-2025-Financial-Results-and-Business-Update.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186043/0/en/Immatics-Achieves-Clinical-Proof-of-Concept-of-its-Next-Generation-TCR-Bispecific-TCER-Pipeline-with-Data-on-IMA402-PRAME-and-IMA401-MAGEA4-8-and-Announces-Next-Development-Steps.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/10/27/3174433/0/en/Immatics-Appoints-Amie-Krause-as-Chief-People-Officer.html

GLOBENEWSWIRE
27 Oct 2025

https://www.globenewswire.com/news-release/2025/10/20/3169544/0/en/Immatics-Highlights-Compelling-Anti-Tumor-Activity-of-Anzu-cel-PRAME-Cell-Therapy-in-Metastatic-Uveal-Melanoma-at-the-ESMO-2025-Presidential-Symposium.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159333/0/en/Immatics-Appoints-Venkat-Ramanan-as-Chief-Financial-Officer.html

GLOBENEWSWIRE
01 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty